Interactive effects of blood–brain barrier breakdown and Alzheimer's disease biomarker status on cognitive decline in older adults without dementia
Open Access
- 11 November 2025
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (11) , e70910
Abstract
INTRODUCTION: Some research suggests that blood–brain barrier (BBB) integrity is altered in Alzheimer's disease (AD). Few studies have examined markers of BBB integrity and their interactions with AD risk factors on multi‐domain cognition. METHODS: 83 older adults without dementia underwent lumbar puncture, apolipoprotein E (APOE) genotyping, and neuropsychological testing with up to 5 years of follow‐up. Soluble platelet‐derived growth factor receptor beta (sPDGFRβ) was measured in cerebrospinal fluid. RESULTS: Higher baseline sPDGFRβ was associated with better cross‐sectional attention, visuospatial, and executive functioning, but with steeper longitudinal decline in executive function. When considering AD risk status, higher sPDGFRβ was associated with faster longitudinal decline in all cognitive domains in biomarker‐positive relative to biomarker‐negative individuals and in language in APOE ɛ4‐positive relative to ɛ4‐negative individuals. DISCUSSION: Elevated sPDGFRβ may increase risk of cognitive decline, particularly in individuals with a higher risk for AD. Future studies should explore mechanisms that contribute to these relationships. Highlights: Cerebrospinal fluid (CSF) soluble platelet‐derived growth factor receptor beta (sPDGFRβ) is a promising marker of blood–brain barrier (BBB) integrity. Higher sPDGFRβ was cross‐sectionally associated with better cognition at baseline. Higher sPDGFRβ was longitudinally associated with steeper decline in cognition, particularly among amyloid beta (Aβ) 42/Aβ40+ individuals. CSF concentration of sPDGFRβ may predict cognitive decline in those with increased dementia risk.Keywords
Funding Information
- Alzheimer's Association (SG‐23‐1038904 QC)
- European Union Agency for Cybersecurity (JPND2019‐466‐236)
- Hjärnfonden (#ALZ2022‐0006)
- Hjärnfonden (#FO2024‐0048‐TK‐130)
- Hjärnfonden (FO2024‐0048‐HK‐24)
- National Institutes of Health (RF1 AG082726)
This publication has 71 references indexed in Scilit:
- Cerebral perfusion and oxygenation differences in Alzheimer's disease riskNeurobiology of Aging, 2009
- Altered plasma cytokine levels in Alzheimer's disease: Correlation with the disease progressionImmunology Letters, 2007
- Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's diseaseJournal of Experimental Medicine, 2007
- Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's diseaseNeurobiology of Aging, 2006
- Intrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer DiseaseArchives of Neurology, 2006
- Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor.1999
- Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironmentProceedings of the National Academy of Sciences, 1998
- Working memory and the self-ordered pointing task: Further evidence of early prefrontal decline in normal agingJournal of Clinical and Experimental Neuropsychology, 1993
- Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's diseaseNeurology, 1993
- Short-term longitudinal change in cognitive performance in later life.Psychology and Aging, 1992